Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

ENDRA Life Sciences (NDRA) Gains from Sales and Divestitures (2021)

ENDRA Life Sciences has reported Gains from Sales and Divestitures over the past 1 years, most recently at $3.9 million for Q4 2021.

Quarterly Gains from Sales and Divestitures changed N/A to $3.9 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Dec 2021, changed N/A year-over-year, with the annual reading at $3.9 million for FY2021, N/A changed from the prior year.
Gains from Sales and Divestitures was $3.9 million for Q4 2021 at ENDRA Life Sciences.
Over five years, Gains from Sales and Divestitures peaked at $3.9 million in Q4 2021 and troughed at $3.9 million in Q4 2021.